Compounded Medication – Prescription Only

This product is a compounded injectable preparation containing bremelanotide, supplied in a sterile injectable vial and dispensed only pursuant to a valid prescription issued by a licensed healthcare provider. Bremelanotide is a synthetic peptide compound. In compounding practice, peptide formulations may be prescribed when a provider determines that individualized formulation or dosing considerations are clinically appropriate for a specific patient. This product is not available for self-selection and may only be dispensed following provider authorization. Compounded medications are not approved by the U.S. Food and Drug Administration (FDA). The FDA does not evaluate compounded formulations for safety, effectiveness, or quality. Compounding is performed by a state-licensed pharmacy pursuant to a patient-specific prescription. This page provides general, non-therapeutic information for educational and compliance purposes only. It does not describe intended use, therapeutic benefit, physiologic effect, symptom relief, or expected clinical outcomes.

General Scientific Information (Non-Therapeutic)

Bremelanotide is referenced in scientific literature for its molecular structure and classification as a synthetic peptide within the melanocortin family. Research has examined its receptor-binding characteristics and biochemical properties in laboratory and controlled research environments. Descriptions of molecular characteristics are provided solely for general scientific context. No claims are made regarding safety, effectiveness, neurologic activity, sexual function, central signaling, or suitability for any particular condition.

Contraindications

Bremelanotide injection should not be used in individuals who have a known hypersensitivity or allergy to bremelanotide, peptide-based compounds, or any component of the compounded formulation; have experienced prior adverse reactions to injectable peptide preparations; or are unable to tolerate injectable therapies as determined by the prescribing healthcare provider.

Use in pregnant or breastfeeding individuals should occur only if a licensed healthcare provider determines that potential risks and benefits have been carefully evaluated.

Warnings and Precautions

Bremelanotide may cause transient increases in blood pressure and decreases in heart rate. Caution is advised in individuals with cardiovascular disease, uncontrolled hypertension, or those receiving medications that affect blood pressure or heart rate. Injectable administration should be performed only as prescribed and supervised by a licensed medical provider. Patients should inform their healthcare provider of all medical conditions, medications, and allergies prior to receiving this compounded formulation.

Potential Side Effects

Reported side effects associated with injectable bremelanotide formulations may include injection site reactions such as pain, redness, swelling, or irritation; nausea; headache; flushing; dizziness or lightheadedness; fatigue; or transient changes in blood pressure or heart rate. Serious adverse reactions are uncommon but may occur. Patients should seek immediate medical attention if they experience symptoms of a severe allergic reaction, significant cardiovascular effects, or unexpected systemic symptoms.